You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
McKesson
Mallinckrodt
Dow
AstraZeneca

Last Updated: April 8, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,278,968

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,278,968
Title:Combination therapy with glutaminase inhibitors
Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.
Inventor(s): Parlati; Francesco (San Francisco, CA), Orford; Keith (Doylestown, PA), Whiting; Sam H. (Seattle, WA)
Assignee: Calithera Biosciences, Inc. (South San Francisco, CA)
Application Number:15/686,403
Patent Claims:1. A method of treating renal cell cancer in a subject, comprising conjointly administering a glutaminase inhibitor and an anticancer agent, wherein: the glutaminase inhibitor is ##STR00034## and the anticancer agent is cabozantinib.

2. The method of claim 1, wherein the cancer is resistant to an anticancer agent selected from cabozantinib, crizotinib, and axitinib.

3. The method of claim 1, further comprising conjointly administering one or more additional chemotherapeutic agents.

4. The method of claim 3, wherein the one or more additional chemotherapeutic agents includes aminoglutethimide, amsacrine, anastrozole, asparaginase, Bacillus Calmette-Guerin vaccine (bcg), bicalutamide, bleomycin, bortezomib, buserelin, busulfan, campothecin, capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dexamethasone, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thalidomide, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, or vinorelbine.

5. The method of claim 1, wherein the method further comprises administering one or more non-chemical methods of cancer treatment.

6. The method of claim 5, wherein the one or more non-chemical methods comprise radiation therapy.

7. The method of claim 6, wherein the one or more non-chemical methods comprise surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination of the foregoing.

Details for Patent 10,278,968

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2036-08-25 RX search
Organon Usa Inc. TICE BCG bacillus calmette-guerin POWDER, FOR SUSPENSION 102821 1 1990-08-24   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2036-08-25 search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2036-08-25 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2036-08-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Medtronic
Moodys
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.